Gilder Gagnon Howe & Co. LLC lowered its stake in shares of AxoGen, Inc (NASDAQ:AXGN) by 21.1% in the third quarter, Holdings Channel reports. The institutional investor owned 445,322 shares of the medical equipment provider’s stock after selling 119,020 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in AxoGen were worth $5,558,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Parallel Advisors LLC raised its position in shares of AxoGen by 9,583.9% in the 3rd quarter. Parallel Advisors LLC now owns 3,002 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 2,971 shares in the last quarter. Advisor Group Inc. raised its holdings in AxoGen by 86.3% in the second quarter. Advisor Group Inc. now owns 2,548 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 1,180 shares in the last quarter. Stonebridge Capital Advisors LLC bought a new position in AxoGen in the second quarter worth about $59,000. Synovus Financial Corp purchased a new stake in shares of AxoGen during the third quarter valued at about $66,000. Finally, Aperio Group LLC purchased a new stake in shares of AxoGen during the second quarter valued at about $77,000. 83.58% of the stock is currently owned by institutional investors and hedge funds.
Shares of AXGN opened at $16.51 on Wednesday. The company has a 50 day moving average of $14.99 and a two-hundred day moving average of $16.44. The company has a quick ratio of 7.38, a current ratio of 8.20 and a debt-to-equity ratio of 0.01. AxoGen, Inc has a twelve month low of $10.91 and a twelve month high of $30.97. The company has a market cap of $635.07 million, a price-to-earnings ratio of -30.57 and a beta of 0.27.
AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. AxoGen had a negative return on equity of 17.82% and a negative net margin of 26.79%. The business had revenue of $28.56 million for the quarter, compared to the consensus estimate of $28.10 million. On average, sell-side analysts expect that AxoGen, Inc will post -0.69 EPS for the current year.
Separately, BidaskClub upgraded shares of AxoGen from a “strong sell” rating to a “sell” rating in a report on Monday, November 25th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. AxoGen presently has an average rating of “Buy” and a consensus price target of $25.00.
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Recommended Story: Cash Flow Analysis in Stock Selection
Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc (NASDAQ:AXGN).
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.